checkAd
    Startseite > Aktien > Atossa Therapeutics > Nachrichten
    Atossa Therapeutics Aktie
    1,5200
     
    USD
    -0,65 %
    -0,0100 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,5200
     
    USD
    28.600 STK
    Geldkurs 02.05.24
    1,5300
     
    USD
    8.500 STK
    Briefkurs 02.05.24
    ISIN: US04962H5063 · WKN: A2JJ99 · SYM: ATOS · USA

    Neueste Nachrichten

    Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
    29.04.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO) in Women with ER+/HER2- Breast Cancer
    15.04.24 · globenewswire · Atossa Therapeutics
    Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
    11.04.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
    09.04.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
    01.04.24 · globenewswire · Atossa Therapeutics
    Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 20.03.2024
    20.03.24 · wO Chartvergleich · Avista
    Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
    19.03.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
    18.03.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
    12.03.24 · globenewswire · Atossa Therapeutics
    Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
    06.03.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
    22.02.24 · globenewswire · Atossa Therapeutics
    Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
    07.02.24 · globenewswire · Atossa Therapeutics